New treatments for advanced/metastatic RAS-mutated NSCLC presented at ELCC25 – ESMO
ESMO – European Society for Medical Oncology shared a post on LinkedIn:
“Clinical Trials presented at ELCC25 evaluated the efficacy and safety of new treatments for advanced/metastatic RAS-mutated NSCLC.
According to updated data from the KRYSTAL-7 phase II trial, adagrasib plus pembrolizumab continued to have encouraging efficacy in patients with KRASG12C-mutated NSCLC and PD-L1 ≥50%. Median progression-free survival (PFS) was 27.7 months but high rates of grade ≥3 adverse events were noted.
In an updated analysis from the KROCUS phase II trial investigating fulzerasib plus cetuximab in untreated patients with KRASG12C-mutated NSCLC, median PFS was 12.5 months with consistent results across levels of PD-L1 expression and manageable toxicity.
Promising phase I/Ib trial findings were also presented for daraxonrasib in previously treated RAS-mutated NSCLC.
Read the full news article in the ESMO Daily Reporter.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023